Inflammation-induced sensitization of the brain in term infants

Developmental Medicine and Child Neurology

Volumn 57, Issue S3, 2015, Pages 17-28

  Fleiss, Bobbi ^a,b,c,d,e   Tann, Cally J ^f,g   Degos, Vincent ^a,b,c,d   Sigaut, Stéphanie ^a,b,c,d   Van Steenwinckel, Juliette ^a,b,c,d   Schang, Anne Laure ^a,b,c,d   Kichev, Anton ^e   Robertson, Nicola J ^f   Mallard, Carina ^h   Hagberg, Henrik ^e,i   Gressens, Pierre ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d PremUP   (France)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; DEATH RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; GLUCOCORTICOID; INTERLEUKIN 9; PROSTAGLANDIN; TOLL LIKE RECEPTOR 3;

ARTICLE; BRAIN INJURY; CENTRAL NERVOUS SYSTEM SENSITIZATION; CEREBRAL PALSY; CLINICAL OBSERVATION; FEVER; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFANCY; INFANT MORTALITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEWBORN DISEASE; NEWBORN SEPSIS; PERINATAL PERIOD; PLACENTA DISORDER; PRIORITY JOURNAL; TERM BIRTH; ANIMAL; BRAIN; BRAIN INJURIES; COMPLICATION; CONGENITAL MALFORMATION; FEMALE; FETOMATERNAL TRANSFUSION; GENE EXPRESSION REGULATION; INFANT; INFLAMMATION; NEWBORN; PREGNANCY;

ANIMALS; BRAIN; BRAIN INJURIES; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; INFANT; INFANT, NEWBORN; INFLAMMATION; MATERNAL-FETAL EXCHANGE; PREGNANCY;

EID: 84925246443     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.12723     Document Type: Article

References (128)

1. You D, Bastian P, Wu J, Wardlaw T. Levels & Trends in Child Mortality. New York: WHO, World Bank, UN-DESA Population Division, UNICEF, New York. 2013.
2. Lee ACC, Kozuki K, Blencowe H, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at the regional and global levels for 2010 with trends from 1990. Pediatr Res 2013; 74: 50-72.
3. Nelson KB, Leviton A. How much of neonatal encephalopathy is due to birth asphyxia? Am J Dis Child 1991; 145: 1323-31.
4. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev 2010; 86: 329-38.
5. Gunn AJ, Gluckman PD, Gunn TR. Selective head cooling in newborn infants after perinatal asphyxia: a safety study. Pediatrics 1998; 102: 885-92.
6. Gunn AJ, Parer JT, Mallard EC, Williams CE, Gluckman PD. Cerebral histological and electrocorticographic changes after asphyxia in fetal sheep. Pediatr Res 1992; 31: 486-91.
7. Badawi N, Kurinczuk JJ, Keogh JM, et al. Antepartum risk factors for newborn encephalopathy: the Western Australian case-control study. Br Med J 1998; 317: 1549-53.
8. Badawi N, Kurinczuk JJ, Keogh JM, et al. Intrapartum risk factors for newborn encephalopathy: the Western Australian case-control study. Br Med J 1998; 317: 1554-8.
9. Ellis M, Manandhar N, Manandhar DS, Costello AM. Risk factors for neonatal encephalopathy in Kathmandu, Nepal, a developing country: unmatched case-control study. Br Med J 2000; 320: 1229-36.
10. Martinez-Biarge M, Diez-Sebastian J, Wustoff CW, Mercuri E, Cowan FM. Antepartum and intrapartum factors preceding neonatal hypoxic-ischemic encephalopathy. Pediatrics 2013; 132: e952-9.
11. Ellis M, Costello AM. Antepartum risk factors for newborn encephalopathy. Intrapartum risk factors are important in developing world. Br Med J 1999; 318: 1414 (author reply 5).
12. Peebles DM, Wyatt JS. Synergy between antenatal exposure to infection and intrapartum events in causation of perinatal brain injury at term. BJOG 2002; 109: 737-9.
13. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. Ann Neurol 2012; 71: 444-57.
14. Kendall G, Peebles D. Acute fetal hypoxia: the modulating effect of infection. Early Hum Dev 2005; 81: 27-34.
15. Foster-Barber A, Ferriero DM. Neonatal encephalopathy in the term infant: neuroimaging and inflammatory cytokines. Ment Retard Dev Disabil Res Rev 2002; 8: 20-4.
16. Wang X, Hagberg H, Nie C, et al. Dual role of intrauterine immune challenge on neonatal and adult brain vulnerability to hypoxia-ischemia. J Neuropathol Exp Neurol 2007; 66: 552-61.
17. Rousset CI, Kassem J, Olivier P, et al. Antenatal bacterial endotoxin sensitizes the immature rat brain to postnatal excitotoxic injury. J Neuropathol Exp Neurol 2008; 67: 994-1000.
18. Rangon CM, Fortes S, Lelievre V, et al. Chronic mild stress during gestation worsens neonatal brain lesions in mice. J Neurosci 2007; 27: 7532-40.
19. Olivier P, Baud O, Bouslama M, et al. Moderate growth restriction: deleterious and protective effects on white matter damage. Neurobiol Dis 2007; 26: 253-63.
20. Dommergues MA, Patkai J, Renauld JC, Evrard P, Gressens P. Proinflammatory cytokines and interleukin-9 exacerbate excitotoxic lesions of the newborn murine neopallium. Ann Neurol 2000; 47: 54-63.
21. Eklind S, Mallard C, Leverin AL, et al. Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemic injury. Eur J Neurosci 2001; 13: 1101-6.
22. Fontaine RH, Olivier P, Massonneau V, et al. Vulnerability of white matter towards antenatal hypoxia is linked to a species-dependent regulation of glutamate receptor subunits. Proc Nalt Acad Sci USA 2008; 105: 16779-84.
23. Romero R, Velez Edwards DR, Kusanovic JP, et al. Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol 2010; 202: 431.e1-34.
24. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998; 44: 665-75.
25. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42: 1-8.
26. Lin CY, Chang YC, Wang ST, et al. Altered inflammatory responses in preterm children with cerebral palsy. Ann Neurol 2010; 68: 204-12.
27. Kasdorf E, Perlman JM. Hyperthermia, inflammation, and perinatal brain injury. Pediatr Neurol 2013; 49: 8-14.
28. Menon R, Taylor RN, Fortunato SJ. Chorioamnionitis - a complex pathophysiologic syndrome. Placenta 2010; 31: 113-20.
29. Blume H, Li C, Loch CM, Koepsell TD. Intrapartum fever and choriamnionitis as risks for encephalopathy in term newborns: a case-control study. Dev Med Child Neurol 2008; 50: 19-24.
30. Redline RW. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonatal Med 2006; 11: 296-301.
31. Impey L, Greenwood C, MacQuillan K, Reynolds M, Sheil O. Fever in labour and neonatal encephalopathy: a prospective cohort study. BJOG 2001; 108: 594-7.
32. Impey LW, Greenwood CE, Black RS, et al. The relationship between intrapartum maternal fever and neonatal acidosis as risk factors for neonatal encephalopathy. Am J Obstet Gynecol 2008; 198: 49.e1-6.
33. Nelson KB, Grether JK. Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. Am J Obstet Gynecol 1998; 179: 507-13.
34. Nelson KB, Ellenberg JH. Epidemiology of cerebral palsy. Adv Neurol 1978; 19: 421-35.
35. Peebles D. Intrauterine Infection and Perinatal Brain Injury. Scientific Advisory Committee Opinion Paper. London: Royal College of Obstetrics & Gynecology, 2007.
36. Chalak L, Sánchez P, Adams-Huet B, et al. Biomarkers for severity of neonatal hypoxic-ischemic encephalopathy and outcomes in newborns receiving hypothermia therapy. J Pediatr 2013; 162: 35-41.
37. Liu F, McCullough LD. Inflammatory responses in hypoxic ischemic encephalopathy. Acta Pharmacol Sin 2013; 34: 1121-30.
38. Shalak LF, Laptook AR, Jafri HS, Ramilo O, Perlman JM. Clinical chorioamnionitis, elevated cytokines, and brain injury in term infants. Pediatrics 2002; 110: 673-80.
39. Iwamoto A, Seward N, Prost A, et al. Maternal infection and risk of intrapartum death: a population based observational study in South Asia. BMC Pregnancy Childbirth 2013; 13: 245.
40. Nelson KB, Bingham P, Edwards EM, et al. Antecedants of Neonatal Encephalopathy in the Vermont Oxford Network Emecephalopathy Register. Pediatrics 2012; 130: 878.
41. Jenster M, Bonifacio S, Ruel T, et al. Maternal or neonatal infection: association with neonatal encephalopathy outcomes. Pediatr Res 2014; 76: 93-9.
42. Jacobs S, Berg M, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev 2013; 1: CD003311.
43. Houben ML, Nikkels PG, van Bleek GM, et al. The association between intrauterine inflammation and spontaneous vaginal delivery at term: a cross-sectional study. PLoS One 2009; 10: e6572.
44. Bartha AI, Foster-Barber A, Miller SP, et al. Neonatal encephalopathy: association of cytokines with MR spectroscopy and outcome. Pediatr Res 2004; 56: 960-6.
45. Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy; a meta-analysis. J Am Med Assoc 2000; 284: 1417-24.
46. Redline RW, O'Riordan MA. Placental lesions associated with cerebral palsy and neurologic impairment following term birth. Arch Pathol Lab Med 2000; 124: 1785-91.
47. Harteman JC, Nikkels PG, Benders MJ, et al. Placental pathology in full-term infants with hypoxic-ischemic neonatal encephalopathy and association with magnetic resonance imaging pattern of brain injury. J Pediatr 2013; 163: 968-95.e2.
48. Tann CJ, Nakakeeto M, Kutinczuk JJ, et al. The Neonatal Society Summer Meeting. Edinburgh: John McIntyre Conference Centre, Pollock Halls, 2013. http://www.neonatalsociety.ac.uk/meetings/2013_summer_abstracts.pdf.
49. Hayes B, Cooley S, Donnelly J, et al. The placenta in infants >36 weeks gestation with neonatal encephalopathy: a case control study. Arch Dis Child Fetal Neonatal Ed 2013; 98: F233-40.
50. Wintermark P, Boyd T, Gregas MC, Labrecque M, Hansen A. Placental pathology in apshyxiated newborns meeting the criteria for therapeutic hypothermia. Am J Obstet Gynecol 2010; 203: 597.e1-9.
51. Robertson NJ, Nakakeeto M, Hagmann C, et al. Therapeutic hypothermia for birth asphyxia in low-resource settings: a pilot randomised controlled trial. Lancet 2008; 372: 801-3.
52. Redline RW. Placental Pathology: a systematic approach with clinical correlations. Placenta 2008; 22: S86-91.
53. Boog G. Chronic villitis of unknown etiology. Eur J Obstet Gynecol Reprod Biol 2008; 136: 9-15.
54. Rice JE 3rd, Vannucci RC, Brierley JB. The influence of immaturity on hypoxic-ischemic brain damage in the rat. Ann Neurol 1981; 9: 131-41.
55. Bona E, Andersson AL, Blomgren K, et al. Chemokine and inflammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res 1999; 45: 500-9.
56. Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like lesions. J Neuropathol Exp Neurol 1995; 54: 358-70.
57. Dicou E, Rangon CM, Guimiot F, Spedding M, Gressens P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain. Brain Res 2003; 970: 221-5.
58. Stridh L, Mottahedin A, Johansson ME, et al. Toll-like receptor-3 activation increases the vulnerability of the neonatal brain to hypoxia-ischemia. J Neurosci 2013; 33: 12041-51.
59. Wang X, Stridh L, Li W, et al. Lipopolysaccharide sensitizes neonatal hypoxic-ischemic brain injury in a MyD88-dependent manner. J Immunol 2009; 183: 7471-7.
60. Fleiss B, Nilsson MK, Blomgren K, Mallard C. Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J Neuroinflammation 2012; 9: 70.
61. Patkai J, Mesples B, Dommergues MA, et al. Deleterious effects of IL-9-activated mast cells and neuroprotection by antihistamine drugs in the developing mouse brain. Pediatr Res 2001; 50: 222-30.
62. Eklind S, Mallard C, Arvidsson P, Hagberg H. Lipopolysaccharide induces both a primary and a secondary phase of sensitization in the developing rat brain. Pediatr Res 2005; 58: 112-6.
63. Lin HY, Huang CC, Chang KF. Lipopolysaccharide preconditioning reduces neuroinflammation against hypoxic ischemia and provides long-term outcome of neuroprotection in neonatal rat. Pediatr Res 2009; 66: 254-9.
64. Favrais G, Schwendimann L, Gressens P, Lelievre V. Cyclooxygenase-2 mediates the sensitizing effects of systemic IL-1-beta on excitotoxic brain lesions in newborn mice. Neurobiol Dis 2007; 25: 496-505.
65. Aden U, Favrais G, Plaisant F, et al. Systemic inflammation sensitizes the neonatal brain to excitotoxicity through a pro-/anti-inflammatory imbalance: key role of TNFalpha pathway and protection by etanercept. Brain Behav Immun 2010; 24: 747-58.
66. Yang L, Sameshima H, Yamaguchi M, Ikenoue T. Expression of inducible nitric oxide synthase and cyclooxygenase-2 mRNA in brain damage induced by lipopolysaccharide and intermittent hypoxia-ischemia in neonatal rats. J Obstet Gynaecol Res 2005; 31: 185-91.
67. Girard S, Sebire H, Brochu ME, et al. Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or hypoxic-ischemic injuries. Brain Behav Immun 2012; 26: 1331-9.
68. Kendall GS, Hristova M, Horn S, et al. TNF gene cluster deletion abolishes lipopolysaccharide-mediated sensitization of the neonatal brain to hypoxic ischemic insult. Lab Invest 2011; 91: 328-41.
69. Van SJ, Schang AL, Chhor V, et al. 11th European Meeting on Glial Cell Function in Health and Disease, Berlin, Germany, 2013.
70. Winerdal M, Winerdal ME, Kinn J, et al. Long lasting local and systemic inflammation after cerebral hypoxic ischemia in newborn mice. PLoS One 2012; 7: e36422.
71. Shanks N, Windle RJ, Perks PA, et al. Early-life exposure to endotoxin alters hypothalamic-pituitary-adrenal function and predisposition to inflammation. Proc Natl Acad Sci USA 2000; 97: 5645-50.
72. Ikeda T, Yang L, Ikenoue T, Mallard C, Hagberg H. Endotoxin-induced hypoxic-ischemic tolerance is mediated by up-regulation of corticosterone in neonatal rat. Pediatr Res 2006; 59: 56-60.
73. Ikeda T, Mishima K, Aoo N, et al. Dexamethasone prevents long-lasting learning impairment following a combination of lipopolysaccharide and hypoxia-ischemia in neonatal rats. Am J Obstet Gynecol 2005; 192: 719-26.
74. Degos V, Peineau S, Nijboer C, et al. G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration. Ann Neurol 2013; 73: 667-78.
75. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 2006; 17: 159-65.
76. Alves-Filho JC, Sonego F, Souto FO, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16: 708-12.
77. Nijboer CH, Heijnen CJ, Willemen HL, et al. Cell-specific roles of GRK2 in onset and severity of hypoxic-ischemic brain damage in neonatal mice. Brain Behav Immun 2010; 24: 420-6.
78. Lehnardt S, Lachance C, Patrizi S, et al. The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 2002; 22: 2478-86.
79. Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol 2005; 17: 631-6.
80. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-30.
81. Nijboer CHA, Heijnen CJ, Groenendaal F, et al. Strong neuroprotection by inhibition of NF-kappaB after neonatal hypoxia-ischemia involves apoptotic mechanisms but is independent of cytokines. Stroke 2008; 39: 2129-37.
82. Dean JM, Wang X, Kaindl AM, et al. Microglial MyD88 signaling regulates acute neuronal toxicity of LPS-stimulated microglia in vitro. Brain Behav Immun 2010; 24: 776-83.
83. Yang D, Sun YY, Lin X, et al. Intranasal delivery of cell-penetrating anti-NF-kappaB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury. Exp Neurol 2013; 247: 447-55.
84. Eklind S, Hagberg H, Wang X, et al. Effect of lipopolysaccharide on global gene expression in the immature rat brain. Pediatr Res 2006; 60: 161-8.
85. Hagberg H, Mallard C. Effect of inflammation on central nervous system development and vulnerability. Curr Opin Neurol 2005; 18: 117-23.
86. Taylor DL, Jones F, Kubota ES, Pocock JM. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005; 25: 2952-64.
87. Hoffmann O, Zipp F, Weber JR. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med 2009; 87: 753-63.
88. Yepes M, Brown SAN, Moore EG, et al. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005; 166: 511-20.
89. Aktas O, Schulze-Topphoff U, Zipp F. The role of TRAIL/TRAIL receptors in central nervous system pathology. Front Biosci 2007; 12: 2912-21.
90. Thornton C, Rousset CI, Kichev A, et al. Molecular mechanisms of neonatal brain injury. Neurol Res Int 2012; 2012: 506320.
91. Markus T, Cronberg T, Cilio C, et al. Tumor necrosis factor receptor-1 is essential for LPS-induced sensitization and tolerance to oxygen-glucose deprivation in murine neonatal organotypic hippocampal slices. J Cerebr Blood F Met 2009; 29: 73-86.
92. Yu C, Takeda M, Soliven B. Regulation of cell cycle proteins by TNF-alpha and TGF-beta in cells of oligodendroglial lineage. J Neuroimmunol 2000; 108: 2-10.
93. Andrews T, Zhang P, Bhat NR. TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res 1998; 54: 574-83.
94. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF. Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol 1990; 144: 129-35.
95. Dopp JM, Mackenzie-Graham A, Otero GC, Merrill JE. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia. J Neuroimmunol 1997; 75: 104-12.
96. Genc S, Kizildag S, Genc K, Ates H, Atabey N. Interferon gamma and lipopolysaccharide upregulate TNF-related apoptosis-inducing ligand expression in murine microglia. Immunol Lett 2003; 85: 271-4.
97. Cui M, Wang L, Liang X, et al. Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia. Neurobiol Dis 2010; 39: 138-47.
98. Kitchev A, Thornton C, Rousset C, et al. TRAIL signaling and cell death in the immature CNS after hypoxia-ischemia and inflammation. J Biol Chem 2014; 289: 9430-9.
99. Song HY, Régnier CH, Kirschning CJ, Goeddel DV, Rothe M. Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-kappaB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Nat Acad Sci USA 1997; 94: 9792-6.
100. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-25.
101. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 2003; 100: 8514-9.
102. Mesples B, Fontaine RH, Lelievre V, Launay JM, Gressens P. Neuronal TGF-beta1 mediates IL-9/mast cell interaction and exacerbates excitotoxicity in newborn mice. Neurobiol Dis 2005; 18: 193-205.
103. Robertson NJ, Tan S, Groenendaal F, et al. Which neuroprotective agents are ready for bench to bedside translation in the newborn infant? J Pediatr 2012; 160: 544-52.e4.
104. Gonzalez FF, Ferriero DM. Neuroprotection in the newborn infant. Clin Perinatol 2009; 36: 859-80, vii.
105. Johnston MV, Fatemi A, Wilson MA, Northington F. Treatment advances in neonatal neuroprotection and neurointensive care. Lancet Neurol 2011; 10: 372-82.
106. Sugimoto J, Romani AM, Valentin-Torres AM, et al. Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol 2012; 188: 6338-46.
107. Burd I, Breen K, Friedman A, Chai J, Elovitz MA. Magnesium sulfate reduces inflammation-associated brain injury in fetal mice. Am J Obstet Gynecol 2010; 202: 292.e1-9.
108. Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol 2009; 113: 1327-33.
109. Kimura A, Sakurada S, Ohkuni H, Todome Y, Kurata K. Moderate hypothermia delays proinflammatory cytokine production of human peripheral blood mononuclear cells. Crit Care Med 2002; 30: 1499-502.
110. Polderman KH. Hypothermia, immune suppression and SDD: can we have our cake and eat it? Crit Care 2011; 15: 144.
111. Czeh M, Gressens P, Kaindl AM. The yin and yang of microglia. Dev Neurosci 2011; 33: 199-209.
112. Doring A, Yong VW. The good, the bad and the ugly. Macrophages/microglia with a focus on myelin repair. Front Biosci (Schol Ed) 2011; 3: 846-56.
113. Jenkins D, Lee T, Chiuzan C, et al. Altered circulating leukocytes and their chemokines in a clinical trial of therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatr Crit Care Med 2013; 14: 786-95.
114. Robertson N, Faulkner S, Fleiss B, et al. Melatonin Augments Hypothermic Neuroprotection in a Perinatal Asphyxia Piglet Model. Brain 2013; 136: 90-105.
115. Pei Z, Pang S, Cheung R. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke 2003; 34: 770-5.
116. Gerber J, Lotz M, Ebert S, et al. Melatonin is neuroprotective in experimental Streptococcus pneumoniae meningitis. J Infect Dis 2005; 19: 783-90.
117. Halili MA, Andrews MR, Labzin LI, et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010; 87: 1103-14.
118. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901.
119. Suh HS, Choi S, Khattar P, Choi N, Lee SC. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol 2010; 5: 521-32.
120. Zhang B, West EJ, Van KC, et al. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 2008; 1226: 181-91.
121. Fischer A, Sananbenesi F, Mungenast A, Tsai LH. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010; 31: 605-17.
122. Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010; 132: 10842-6.
123. Yang D, Sun YY, Nemkul N, et al. Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia. Cereb Cortex 2013; 23: 1218-29.
124. Bolouri H, Savman K, Wang W, et al. Innate defence regulator peptide 1018 protects against perinatal brain injury. Ann Neurol 2013; 75: 395-410.
125. Azzopardi DV, Strohm B, Edwards AD, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361: 1349-58.
126. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body hypothermia for infants with hypoxic ischaemic encephalopathy. N Engl J Med 2005; 353: 1574-84.
127. Mourvillier B, Tubach F, van der Beek D, et al. Induced hypothermia in severe bacterial meningitis. J Am Med Assoc 2013; 310: 2174-83.
128. Osredkar D, Thoresen M, Maes E, Flatebo T, Elstad M, Sabir H. Hypothermia is not neuroprotective after infection-sensitized neonatal hypoxic-ischemic brain injury. Resuscitation 2014; 85: 567-72.